128 related articles for article (PubMed ID: 36420610)
21. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
Shin S; Kim M; Lee SJ; Park KS; Lee CH
Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
[TBL] [Abstract][Full Text] [Related]
22. miR-146a negatively regulates NK cell functions via STAT1 signaling.
Xu D; Han Q; Hou Z; Zhang C; Zhang J
Cell Mol Immunol; 2017 Aug; 14(8):712-720. PubMed ID: 26996068
[TBL] [Abstract][Full Text] [Related]
23. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
25. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
26. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
27. The orphan nuclear receptor NR4A1 promotes FcεRI-stimulated mast cell activation and anaphylaxis by counteracting the inhibitory LKB1/AMPK axis.
Jin F; Li X; Deng Y; Timilshina M; Huang B; Kim DY; Chang JH; Ichinose H; Baek SH; Murakami M; Lee YJ; Chang HW
Allergy; 2019 Jun; 74(6):1145-1156. PubMed ID: 30565708
[TBL] [Abstract][Full Text] [Related]
28. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma.
Lee HA; Goh HG; Lee YS; Jung YK; Kim JH; Yim HJ; Lee MG; An H; Jeen YT; Yeon JE; Byun KS; Seo YS
BMC Gastroenterol; 2021 Jun; 21(1):258. PubMed ID: 34118869
[TBL] [Abstract][Full Text] [Related]
29. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
Sung PS; Jang JW
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
[TBL] [Abstract][Full Text] [Related]
30. IFN-γ Induces IL-15
Kim TS; Rha MS; Shin EC
J Immunol; 2022 Jan; 208(2):338-346. PubMed ID: 34893528
[TBL] [Abstract][Full Text] [Related]
31. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.
Yu M; Li Z
Front Med; 2017 Dec; 11(4):509-521. PubMed ID: 28780700
[TBL] [Abstract][Full Text] [Related]
32. NR4A transcription factors limit CAR T cell function in solid tumours.
Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
[TBL] [Abstract][Full Text] [Related]
33. Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells.
Yan Y; Zheng L; Du Q; Cui X; Dong K; Guo Y; Geller DA
Br J Cancer; 2021 Jul; 125(1):101-111. PubMed ID: 33772151
[TBL] [Abstract][Full Text] [Related]
34. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions.
Wu Y; Kuang DM; Pan WD; Wan YL; Lao XM; Wang D; Li XF; Zheng L
Hepatology; 2013 Mar; 57(3):1107-16. PubMed ID: 23225218
[TBL] [Abstract][Full Text] [Related]
35. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
37. Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells.
Kim M; Lee SJ; Shin S; Park KS; Park SY; Lee CH
Sci Rep; 2018 Jul; 8(1):10668. PubMed ID: 30006566
[TBL] [Abstract][Full Text] [Related]
38. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function.
Jiang W; Zhang C; Tian Z; Zhang J
Gene Ther; 2013 Nov; 20(11):1062-9. PubMed ID: 23759701
[TBL] [Abstract][Full Text] [Related]
39. ISG12a and its interaction partner NR4A1 are involved in TRAIL-induced apoptosis in hepatoma cells.
Liu N; Wu Z; Chen A; Chai D; Li L; Zhang L; Zheng J
J Cell Mol Med; 2019 May; 23(5):3520-3529. PubMed ID: 30821058
[TBL] [Abstract][Full Text] [Related]
40. Modulation of antitumour immune responses by intratumoural Stat1 expression.
Messina NL; Banks KM; Vidacs E; Martin BP; Long F; Christiansen AJ; Smyth MJ; Clarke CJ; Johnstone RW
Immunol Cell Biol; 2013 Oct; 91(9):556-67. PubMed ID: 23958683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
